CXCL1 and pancreatic adenocarcinoma: In addition, CXCL1/2/3/4/5/6/7/8/9/10/11/12/13/14/16/17 were altered in 7%, 7%, 7%, 9%, 7%, 8%, 4%, 5%, 8%, 5%, 7%, 1.8%, 4%, 5%, 4%, and 8% of the sequencing data from PAAD samples, respectively (Figure 4B).